For the year ending 2025-12-31, AVTX has $116,458K in assets. $33,409K in debts. $15,858K in cash and cash equivalents.
| Balance Sheets | 2025-12-31 | |||
|---|---|---|---|---|
| Cash and cash equivalents | 15,858 | |||
| Short-term investments | 82,478 | |||
| Prepaid expenses and other current assets | 6,913 | |||
| Restricted cash, current portion | 37 | |||
| Total current assets | 105,286 | |||
| Property and equipment, net | 460 | |||
| Goodwill | 10,502 | |||
| Restricted cash, net of current portion | 210 | |||
| Total assets | 116,458 | |||
| Accounts payable | 137 | |||
| Accrued expenses and other current liabilities | 12,803 | |||
| Derivative liability, current | 0 | |||
| Total current liabilities | 12,940 | |||
| Royalty obligation | 2,000 | |||
| Deferred tax liability, net | 434 | |||
| Derivative liability, non-current | 18,000 | |||
| Other long-term liabilities | 35 | |||
| Total liabilities | 33,409 | |||
| Temporary equity, values issued-Series DPreferred Stock | 0 | |||
| Temporary equity, values issued-Series EPreferred Stock | 0 | |||
| Common stock0.001 par value 200,000,000 shares authorized at december31, 2025 and december31, 2024 18,512,757 and 10,471,934 shares issued and outstanding at december31, 2025 and december31, 2024, respectively | 18 | |||
| Additional paid-in capital | 531,485 | |||
| Accumulated other comprehensive income | 68 | |||
| Accumulated deficit | -448,522 | |||
| Total stockholders equity | 83,049 | |||
| Total liabilities, mezzanine equity and stockholders equity | 116,458 | |||
Avalo Therapeutics, Inc. (AVTX)
Avalo Therapeutics, Inc. (AVTX)